H
Hugh Watson
Researcher at Aarhus University
Publications - 49
Citations - 1364
Hugh Watson is an academic researcher from Aarhus University. The author has contributed to research in topics: Cirrhosis & Ascites. The author has an hindex of 13, co-authored 37 publications receiving 1141 citations. Previous affiliations of Hugh Watson include Aarhus University Hospital.
Papers
More filters
Journal ArticleDOI
102 effects of satavaptan, an oral vasopressin v2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long-term, placebo-controlled study
Journal ArticleDOI
Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites.
TL;DR: This work examined the association between serum sodium, changes in serum Sodium, and HE incidence using data from three randomized trials of satavaptan in cirrhosis patients with ascites in order to identify patients at risk ofHyponatremia.
Journal ArticleDOI
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium
Elsa Solà,Elisa Pose,Daniela Campion,Salvatore Piano,Olivier Roux,Macarena Simón-Talero,Frank Erhard Uschner,Koos de Wit,Giacomo Zaccherini,Carlo Alessandria,Ulrich Beuers,Paolo Caraceni,Claire Francoz,Rajeshwar P. Mookerjee,Jonel Trebicka,Victor Vargas,Miquel Gómez i Serra,Ferran Torres,Sara Montagnese,Aleksander Krag,Ruben Hernaez,Marko Korenjak,Hugh Watson,Juan G. Abraldes,Patrick S. Kamath,Pere Ginès,F. Durand,Maria Martha Bernardi,Cristina Solé,Judit Pich,Isabel Graupera,Laura Napoleone,Carlos Jiménez,Adrià Juanola,Emma Avitabile,Ann T. Ma,Núria Fabrellas,Marta Carol,E. Palacio,M. Aban,T. Lanzillotti,G. Nicolao,M.T. Chiappa,V. Esnault,Alejandro Forner,S. Graf-Dirmeier,Jeltje Helder,Maricela Quintana López,Marta Cervera,M. Pérez-Guasch +49 more
TL;DR: The LiverHope Consortium organized a meeting of experts with the goal of making recommendations for the design of clinical trials and defining appropriate endpoints both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis and Trials aimed at investigating new therapies for the management of each complication of Cirrhosis.
Journal ArticleDOI
What chikungunya teaches us about COVID-19.
Fabrice Simon,Hugh Watson,Jean-Baptiste Meynard,Vincent Pommier de Santi,Jean-Nicolas Tournier +4 more
Journal ArticleDOI
MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites
TL;DR: The Model for Endstage Liver Disease (MELD) score may put patients with severe ascites at a disadvantage because they often have a poor quality of life and high mortality despite a favourable MELD score.